John Crowley, President and CEO of BIO, visited Colorado as part of the BIO on the American Road listening tour. After a visit to Fitzsimons Innovation Community and the labs at ClinImmune and RheumaGen, Crowley sat down for a conversation with Denver’s KOA Radio. They discussed the future of biotechnology and the value of Colorado’s…
The U.S. life sciences real estate market posted positive net absorption in the fourth quarter even as robust construction completions raised the sector’s vacancy rate to 19.7%, according CBRE’s new quarterly figures report. The Q4 numbers indicate gradual improvement across the 13 largest U.S. life sciences markets (including Denver-Boulder) and the potential for that momentum…
The life sciences market continues to evolve as we enter 2025, and its real estate needs are changing as well. Rigid labs are being replaced by adaptable, collaborative spaces that foster innovation. The market demands spaces that meet diverse business needs and accommodate its changing workforce.
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
The new partnership will accelerate delivery of lab space to market. Designed for quick expansion and flexibility to respond to market needs, the development will begin with the 230,000-square-foot Bioscience 4 facility. Bioscience 4 will be the perfect space for health innovators on the frontlines of the most exciting progress in healthcare.
SALT LAKE CITY and BOCA RATON, Fla. – May 15, 2023 – Nusano , Inc., a company reshaping the production of cancer-fighting radioisotopes, and PharmaLogic Holdings Corp. , a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announced the two organizations will collaborate to advance the development of radiopharmaceuticals for diagnostic and…
Fitzsimons Innovation Community releases its Second Annual Innovation Report focused on the momentum our Community members build on our campus to take their discoveries and projects from idea to market.
The company’s off-the-shelf or ‘allogeneic’ therapy tabelecleucel – now given the Ebvallo trade name – has been approved by the European Commission as a second-line treatment for a rare and potentially deadly cancer that afflicts some organ or bone marrow transplant recipients.
The University of Colorado Anschutz Medical Campus has been named one of the top academic institutions in the world for innovation, according to Nature’s 2022 Innovation Index report. The report ranked CU Anschutz in the top four universities globally for forging the strongest innovations links.